CSL is a global biopharma company developing lifesaving medicines and vaccines. Through CSL Behring, CSL Seqirus and CSL Vifor, the company delivers biotherapies for rare and serious diseases, influenza vaccines, and treatments for iron deficiency and nephrology. With 29,000 people and operations in over 100 countries, CSL combines commercial strength, R&D focus and operational excellence to bring innovations from lab to patient. The company manufactures plasma-derived therapies for bleeding disorders, immune deficiencies and hereditary angioedema, operates one of the world's largest influenza vaccine programmes, and provides treatments for kidney disease and iron deficiency. Founded in 1916 to serve the health needs of Australia during wartime, CSL today advances clinical trials designed to meet the needs of diverse patient communities worldwide.
29904
Team Members
1916
Founded
Pharma
Sector
Hybrid
Work Environment
A world where innovative biotherapies and vaccines reach every person facing rare disease, pandemic threat or critical health need, transforming medical possibility into enduring patient impact across generations.
CSL saves lives and protects public health by developing, manufacturing and delivering innovative biotherapies and vaccines for patients with rare and serious diseases, combining over a century of biotechnology excellence with relentless R&D to turn scientific breakthrough into treatments people depend on.